Cereno
Cereno Scientific communicates Phase I results in July
Promising 4-month data from Cereno's Expanded Access Program
Cereno Scientific has published 4-month follow-up data from its...
Bioteknik
Additional data strengthens Cereno's CS1 in PAH
After promising phase IIa results for the drug candidate CS1 against...
Cereno Scientific to evaluate CS1 with advanced imaging technology
Cereno Scientific announces that a substudy with CS1...
News roundup Monday, December 2
Biovica
Significant third quarter for Cereno
Cereno Scientific delivered a strong Q3 2024, not...
News roundup Tuesday, October 8
From Seed to Success 2024
Cereno Scientific comments on the Phase IIa study results
The study was conducted on the company's top candidate CS1 in the...
Intervju
Video
The news sweep Friday 15 December
The latest from BioStock
The news sweep Wednesday 13 December
The latest from BioStock
Cereno's CEO on study progress during Q2
For the biotechnology company Cereno Scientific, the second quarter of the year has...
Intervju
Video
Cereno's CEO on the goals for 2023
Sten R. Sörensen, CEO of Cereno Scientific, visited...
Intervju
Video